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Although many aspects of CD4
 
 
 
CD25
 
 
 
 T regulatory (T
 
reg
 
) cell development remain largely 
unknown, signaling through the IL-2R represents one feature for the production of T
 
reg
 
 cells. 
Therefore, the present study was undertaken to further define early developmental steps in 
the production of T
 
reg
 
 cells, including a more precise view on the role of interleukin (IL)-2 in 
this process. After adoptive transfer of wild-type T
 
reg
 
 cells into neonatal IL-2R
 
 
 
 
 
/
 
 
 
 mice, 
only a small fraction of donor T
 
reg
 
 cells selectively seeded the lymph node (LN). These donor 
T
 
reg
 
 cells underwent rapid and extensive IL-2–dependent proliferation, followed by 
subsequent trafficking to the spleen. Thus, IL-2 is essential for T
 
reg
 
 cell proliferation in 
neonatal LN. The number and distribution of T
 
reg
 
 cells in the periphery of normal neonatal 
mice closely paralleled that seen for IL-2R
 
 
 
 
 
/
 
 
 
 mice that received T
 
reg
 
 cells. However, for 
normal neonates, blockade of IL-2 decreased T
 
reg
 
 cells in both the thymus and LN. Therefore, 
two steps of T
 
reg
 
 cell development depend upon IL-2 in neonatal mice, thymus production, 
and subsequent expansion in the LN.
 
CD4
 
 
 
CD25
 
 
 
 T regulatory (T
 
reg
 
) cells represent
a critical T cell subset that suppresses peripheral
autoreactive T cells that escape thymic negative
selection (1, 2). CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells natu-
rally arise in the thymus, in part through high-
affinity interactions with self-peptide–MHC
complexes (3, 4). The expression of the tran-
scription factor Foxp3 is also required for
thymic development of T
 
reg
 
 cells (5–7). In the
absence of functional Foxp3, T
 
reg
 
 cells are not
produced and such mice die within 3 wk of age
due to a rapid lymphoproliferative disorder.
There is substantial evidence indicating
that IL-2–IL-2R–dependent events play a role
in the production of CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells.
Similar to mice with impaired Foxp3, IL-2–,
IL-2R
 
 
 
–, and IL-2R
 
 
 
–deficient mice exhibit
an analogous lethal lymphoproliferative disor-
der accompanied with severe autoimmunity
(8–10). IL-2 and IL-2R
 
 
 
 knockout mice con-
tain severely reduced numbers of CD4
 
 
 
CD25
 
 
 
T
 
reg
 
 cells (11, 12). More importantly, correcting
the production of T
 
reg
 
 cells in such mice, either
in mixed bone marrow or T cell chimeric
mice, led to inhibition of uncontrolled T cell
proliferation and autoimmunity (13–15). In
related experiments, the adoptive transfer of
wild-type T
 
reg
 
 cells into neonatal IL-2R
 
 
 
 
 
/
 
 
 
mice resulted in substantial proliferation and
stable engraftment of the donor T
 
reg
 
 cells such
that these mice lived a normal disease-free life-
span. This protection was contingent upon
donor T
 
reg
 
 cells expressing a functional IL-2R
and the host producing IL-2 (12). Further-
more, thymus-specific expression of IL-2R
 
 
 
in IL-2R
 
 
 
 
 
/
 
 
 
 mice restored the production of
functional CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells and pre-
vented lethal autoimmunity, indicating that
the IL-2–IL-2R interaction is necessary during
thymic T
 
reg
 
 cell development (12, 16).
Although several features for the production
of T
 
reg
 
 cells have been defined, many aspects of
CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cell development remain
largely unknown. Current data point to a role
for IL-2 in both the thymus and periphery, but
the relative importance and the relationship of
thymic versus peripheral requirements for IL-2
are not yet apparent. Of special interest is a
more detailed understanding of the initial steps
for the expansion of T
 
reg
 
 cells after transfer into
neonatal IL-2R
 
 
 
 
 
/
 
 
 
 mice, as this leads to
long-term engraftment and persistent suppression
of autoimmunity by the donor cell inoculum.
The most compelling data for IL-2 in T
 
reg
 
cell production relies on IL-2– and IL-2R
 
 
 
–
deficient mice. The extent that these models
recapitulate the normal process for T
 
reg
 
 cell
development remains an open issue. With these
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questions in mind, the present study was undertaken to fur-
ther define early developmental steps in the production of
T
 
reg
 
 cells, including a more precise view on the role of IL-2
in this process. Our data support a model in which IL-2 crit-
ically acts within the thymus and neonatal lymph nodes to
promote the expansion of T
 
reg
 
 cells.
 
RESULTS
Fate of CD4
 
 
 
CD25
 
 
 
 T regulatory cells in neonatal mice
 
Past studies have demonstrated that 4 weeks after adoptive
transfer of normal CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells into IL-2R
 
 
 
–
deficient mice, donor T
 
reg
 
 cells expanded at least 10–20-fold
and were readily detected in the spleen and lymph nodes,
but not in the thymus, of recipient mice (12). To evalu-
ate early events during T
 
reg
 
 cell engraftment, GFP
 
 
 
 CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells were adoptively transferred into neonatal
IL-2R
 
 
 
 
 
/
 
 
 
 mice. FACS analysis 6 d later revealed that
GFP
 
 
 
 CD4
 
 
 
 donor cells were readily seen in the lymph
nodes whereas a very low, but a consistently detectable frac-
tion, of GFP
 
 
 
 cells was found in the spleen (Fig. 1, A and B).
Although there was a very small number of donor cells in
the spleen, the fraction of donor cells within the CD4
 
 
 
 pop-
ulation was similar to that seen in the lymph nodes (Fig. 1 B).
By contrast, essentially no GFP
 
 
 
 cells were found in the thy-
mus and bone marrow when examined from 6–20 d after
transfer (Fig. 1, A and B). Even as early as 2 d after transfer,
essentially no donor cells were found within the thymus
(unpublished data). For the lymph nodes, on day 6 
 
 
 
3–4%
of the cells were GFP
 
 
 
 and this fraction remained relatively
constant during the first 3 wk after birth, whereas the frac-
tion GFP
 
 
 
 cells in the spleen noticeably increased on day 20
(Fig. 1, A and B). Furthermore, at each time point, essen-
tially all GFP
 
 
 
 donor cells in the lymph nodes and most in
the spleen were CD4
 
 
 
 T cells (Fig. 1 C), and a large major-
ity of the donor CD4
 
 
 
 T cells coexpressed CD25 (Fig. 1 D).
 
Expansion of T
 
reg
 
 cells in neonatal mice
 
To directly assess the proliferative rate of T
 
reg
 
 cells, 5-(and 6-)
carboxyfluorescein diacetate, succinimidyl ester (CFSE)-
labeled CD45.1
 
 
 
 CD4
 
 
 
CD25
 
 
 
 T
 
reg
 
 cells were adoptively
transferred into neonatal IL-2R
 
 
 
 
 
/
 
 
 
 mice (CD45.2). In the
spleen, 2 d after the adoptive transfer, 
 
 
 
1.8% of the spleen
contained donor CD45.1
 
 
 
 cells with the majority of these
cells remaining CFSE
 
hi
 
, indicating that these cells had not
undergone proliferation (Fig. 2 A). At this time many of
these donor cells had lost CD25 expression. At 4 and 6 d af-
ter transfer, there was nearly a 10-fold decrease in the frac-
tion of CD45.1
 
 
 
 donor cells within the spleen (Fig. 2, A
and B), and the CD4
 
 
 
 donor cells did not dilute CFSE. As
we have been unable to detect donor cells in nonlymphoid
tissue on day 6 (unpublished data), these data suggest that
most of the donor cells that seeded the spleen may have un-
dergone apoptosis.
In marked contrast, within the lymph nodes 6 d after
adoptive transfer, which was the earliest time point that
lymph nodes could be collected from neonatal mice, 
 
 
 
50%
of the donor CD45.1
 
 
 
 cells were CFSE negative, indicating
that these cells divided at least eight times (Fig. 2 B). These
data demonstrate a very high proliferative potential of T
 
reg
Figure 1. Initial appearance of CD4 CD25  Treg cells in the lymph 
nodes of neonatal mice. Newborn C57BL/6 IL-2R  /  mice received puri-
fied GFP-CD4 CD25  T cells (4–5   105) and 6–20 d after transfer, spleen 
(SP), lymph node (LN), bone marrow (BM), and thymus cells from individual 
recipient mice were subjected to FACS analysis. (A) Dot plots for donor cells 
based on CD4 and GFP expression. The percent of cells expressing CD4 
and/or GFP is indicated in appropriate quadrant. (B) The percent of donor 
GFP  cells (left) or donor GFP CD4  of the total CD4  cells (right) in the 
indicated organ. Data are mean   SEM for three to five animals per day. 
(C) Dot plots for CD4 and CD8 expression for GFP  donor cells. The percent 
of cells expressing CD4 or CD8 is indicated in the appropriate quadrant. 
(D) CD25 expression for CD4  GFP  donor cells. The percent of cells 
expressing CD25 is indicated in the upper right corner of each histogram. 
Data in A, C, and D are representative of three to five animals per day. 
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cells in neonatal IL-2R  / mice. At this time, most of the
lymph nodes were collected from these neonatal mice (total
cellularity of  2   106) and on average  3% or 6   104 of
these were donor Treg cells. Based on the mean fluorescent
intensity of all donor cells, the engrafting Treg cells were on
average the progeny of four to six cell divisions. Therefore,
we estimate that the donor Treg cells within the lymph nodes
were derived from  1,000 to 4,000 cells. At 2 and 3 wk af-
ter transfer, virtually all of the donor cells in the lymph nodes
had lost CFSE staining (Fig. 2 B), indicating that these cells
were progeny that had undergone substantial proliferation.
Approximately 85% of the donor CD45.1  donor cells
in the lymph nodes at day 6 were CD4 CD25  T cells (Fig.
2 C) regardless of whether they had under gone extensive
(CFSElo/neg) or minimal proliferation (CFSEhi; unpublished
data). Most donor cells in the lymph nodes (80%) on days 13
and 20 after transfer coexpressed CD4 and CD25 (Fig. 2 C).
With respect to the spleen, the few donor cells present at day
6 were contained within two subsets, CFSEneg and CFSEhi.
For the donor cells that were found in the nondividing CF-
SEhi subpopulation, most coexpressed CD4 and CD25
whereas the majority of the rapidly proliferating splenic do-
nor cells were CD4  and CD25  cells (unpublished data).
Furthermore, a CFSE  intermediate cell population was not
detected in the spleen at any of the time points (Fig. 2, A
and B), suggesting that the CFSEneg cells were not derived
from dividing progeny within this organ. Importantly, only
by 3 wk after transfer was a substantial population of donor
(CD45.1 ) cells detected within the spleen, which were CF-
SEneg (Fig. 2 B), and  70% of these donor cells were
CD4 CD25  T cells (Fig. 2 C). Collectively, these data in-
dicate that donor CD4 CD25  Treg cells first undergo ex-
tensive proliferation within the lymph nodes of neonatal
mice and raise the possibility that these progeny may subse-
quently home and populate the spleen.
Treg cell production in peripheral lymphoid tissue of normal 
and Tg /  mice
The extent that the engraftment and proliferation of Treg
cells in this adoptive transfer model recapitulates the normal
processes for Treg cells was first evaluated by quantifying Treg
cells in the lymph nodes and spleen of normal C57BL/6
mice. As transgenic thymic expression of IL-2R  in IL-
2R –deficient mice (Tg /  mice) results in the production
of Treg cells (12), these results were compared with that
obtained for donor CD4 CD25  T reg cells transferred
into neonatal IL-2R  /  mice. In each mouse model,
CD4 CD25  T cells were first readily detected in the day 6
neonatal lymph nodes (Fig. 3 A). At this time very few
CD4 CD25  T cells were seen in the spleen, but both the
percentage and number of splenic Treg cells increased to a
readily measurable number by 20 d of age (Fig. 3 B). More-
over, the overall percentage and cell number of Treg cells in
the lymph node and spleen from 6 to 20-d-old mice ap-
proximated that seen for the adoptively transferred IL-
Figure 2. CD4 CD25  Treg cells extensively proliferate in the lymph 
nodes of neonatal mice. Newborn C57BL/6 IL-2R  /  mice received 
purified CD45.1  CFSE-labeled CD4 CD25  T cells (4–5   105) and 2–20 d 
after transfer, spleen (SP), and lymph node (LN) cells from individual recip-
ient mice were subjected to FACS analysis. (A) Dot plots are shown for 
CD45.1 and CD4 expression (top) or CD25 and CFSE expression for 
CD45.1 CD4  donor cells (bottom). The percent of donor CD4  cells is 
indicated in the upper right corner of top dot plots. A total of 105 or 106 
splenic cells were collected from 2- or 4-d-old mice, respectively. (B) Dot 
plots are shown for CD45.1 and CFSE expression. The percent of donor 
cells is indicated in the upper right corner of each dot plot. (C) Dot plots 
depicting CD4 and CD25 expression for CD45.1  donor cells. The percent 
of cells expressing CD4 and CD25 of the gated populations is indicated in 
the upper right corner of the dot plots. Data in A and B are representative 
of two to five animals per day.IL-2 IN TREG CELL DEVELOPMENT | Bayer et al. 772
2R  /  mice (Fig. 3, A and B). One exception was that the
lymph nodes and spleen of neonatal Tg /  mice contained
a somewhat higher percentage and absolute number of
CD4 CD25  T cells (Fig. 3, A and B). This finding is con-
sistent with previous data that showed more CD4 CD25 
T cells in the thymus, spleen, and lymph nodes of adult
Tg /  mice (12).
Phenotypic analysis of lymph node (Fig. 3 C) and splenic
(unpublished data) derived CD4 CD25  T cells from nor-
mal, Tg / , and adoptively transferred IL-2R  /  neonatal
mice indicated that the majority of these cells were CD69neg
and CD62Lhigh, a phenotype associated with Treg cells rather
than recently activated T cells. When compared with normal
C57BL/6 mice, Tg /  mice contained a somewhat higher
fraction of CD62Lhigh cells whereas the adoptively trans-
ferred donor cells contained a lower fraction of these cells.
Glucocorticoid-induced TNF receptor (GITR) was ex-
pressed on essentially all CD4 CD25  cells from these three
types of mice (unpublished data). In contrast, CD103, an-
other marker associated with Treg cells (17), was expressed on
a higher fraction of CD4 CD25  donor cells from the
adoptively transferred mice, especially 14–20 d after transfer.
Collectively, these data indicate that the adoptive transfer of
Treg cells into IL-2R  /  mice largely follows the develop-
mental scheme operative in normal and Tg /  mice.
Role of IL-2 in early development of T regulatory cells
CFSE-labeled normal Treg cells were adoptively transferred
into neonatal IL-2R  /  mice in the absence or presence of
anti–IL-2 mAb to test the extent that the initial engraftment
and proliferation of the donor Treg cells in the lymph nodes
depended upon IL-2 (Fig. 4). In control treated mice (n   3),
CD45.1 donor cells (4.4   0.3%) were readily detected (Fig.
4 A), with the vast majority of the cells expressing CD4 and
CD25 (Fig. 4 B). In contrast, for anti–IL-2–treated mice
(n   3), far fewer donor cells (1.0   0.1%) were detected in
the lymph nodes and many of these were not CD4  and
CD25  cells (Fig.4, A and B). As lymph node cell yields
were equivalent in both groups of mice, this lower percent-
age directly reflected differences in the absolute cell number.
When correcting these data for the fraction of CD45.1  do-
nor cells that coexpressed CD4 and CD25, there was on av-
erage an 83.4% reduction of Treg cells in the lymph nodes of
the anti–IL-2–treated recipients. However, for the few re-
sidual CD4 CD25  T cells after treatment with anti–IL-2,
many fully diluted CFSE (Fig. 4 C), suggesting that these
cells were rapidly proliferating cells. It is not possible to dis-
criminate whether this reflects IL-2–independent prolifera-
tion or some inefficiency of the anti–IL-2 blockade.
To further explore the role of IL-2 in early neonatal life,
normal C57BL/6 mice were also treated with anti–IL-2
Figure 3. Adoptive transfer of Treg cells into IL-2R  /  mice largely 
follows the developmental scheme operative in normal mice. FACS 
analysis of lymph node and spleen cells was performed for 6–20-d-old mice, 
as indicated. The percent CD4- and CD25-positive cells (left) or the absolute 
number of CD4 CD25  (right) in the (A) lymph node and (B) spleen. 
The absolute number of CD4 CD25  T cells was calculated from the percent 
CD4 CD25  cells in the lymph node and spleen times the number of cells in 
these organs. Data are mean   SEM for three to seven mice per day per 
group. (C) CD69, CD62L, or CD103 expression for lymph node CD4 CD25  
T cells (n   3–5 animals per group per day).JEM VOL. 201, March 7, 2005 773
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mAb within the first 24 h after birth. 1 wk later, the fraction
of CD4 CD25  T cells was substantially reduced in the
lymph nodes of the anti–IL-2–treated neonates (Fig. 5 A).
Anti–IL-2 also resulted in a lower fraction of CD4  CD25 
GITR  T cells (Fig. 5 B), another cell surface phenotype as-
sociated with Treg cells (17, 18). Furthermore, this decrease
does not reflect a requirement for IL-2 to maintain expres-
sion of CD25 (19), as lymph nodes from control and anti–
IL-2–treated mice lacked CD4 CD25-GITRhigh T cells. As
lymph node cellularity was equivalent in both the control
and anti–IL-2–treated groups, the reduced percentage of Treg
cells by anti–IL-2 reflected the actual decrease in Treg cell
number. Thus, these data indicate that IL-2 is normally re-
quired for production of Treg cells during early neonatal life
and is not just a property seen upon transfer of Treg cells to
IL-2R  /  mice.
IL-2 regulates thymic Treg cell production
The preceding experiments indicate that IL-2 is critical for
neonatal lymph node Treg cell expansion. However, our past
work also indicates a role for IL-2 during thymic development
of Treg cells (12, 16). Therefore, we further explored the
contribution of thymic IL-2 for Treg cells. Anti–IL-2 treat-
ment of normal C57BL/6 and Tg /  neonatal mice resulted
in a statistically significant reduction in CD4  “single-positive”
CD25  T cells within the thymus (Fig. 6 A), which was
much more striking for Tg /  mice. The blockade by anti–
IL-2 for Tg /  mice provides direct data that the activity
of the transgenic IL-2R  chain depends upon signaling
through the reconstituted thymic IL-2R. These data also
raise the possibility that the reduction of Treg cells within the
lymph nodes of anti–IL-2–treated normal neonatal mice
might in part be due to an effect on the thymic IL-2–IL-2R
interaction. A decrease was also noted in the percentage of
CD4 CD25 GITR  thymocytes of anti–IL-2–treated nor-
mal C57BL/6 neonatal mice, confirming that Treg cells were
reduced by inhibiting IL-2 (Fig. 6 B).
A population of C57BL/6 thymocytes CD4 CD8 
thymocytes was observed that expressed very high levels of
CD25 and these cells were uniformly GITRneg (Fig. 6 B).
The relationship of these cells to Treg cells is not known
and were not included in analyses shown in Fig. 6 B. The
Figure 4. The initial engraftment and proliferation of Treg cells in 
neonatal lymph nodes requires IL-2. Neonatal IL-2R  /  mice were 
adoptively transferred with CD45.1  CFSE-labeled CD4 CD25  T cells 
(2   105) and received either PBS or  -IL-2 mAb (100  g) on the day of 
transfer and 3 d later. 6 d after transfer, lymph node cells from individual 
recipient mice were subjected to FACS analysis. (A) Histograms of donor 
(CD45.1) engraftment. (B) Dot plots for CD4 and CD25 expression after 
gating on CD45.1  donor cells. (C) Histograms of proliferating donor 
CD4 CD25  T cells based on CFSE staining. n   3 per group.
Figure 5. A Role for IL-2 in early development of CD4 CD25  Treg 
cells. B6 mice received either PBS ( ) or  -IL2 mAb ( ; 100  g) on the day 
and 3 d after birth. 7 d after birth, lymph node cells from individual mice 
were subjected to FACS analysis. (A) The percent of CD4 CD25  T cells. 
Data are mean   SEM for 8–10 animals. (B) Dot plots of CD25 and GITR 
expression (left) and the absolute number of GITR  cells for CD4 CD25  
cells (right). Data were mean   SEM for three to four animals.IL-2 IN TREG CELL DEVELOPMENT | Bayer et al. 774
extremely high levels of CD25 and lack of GITR expression
distinguish these cells from Treg cells found in peripheral
lymphoid tissue that express a somewhat lower level of
CD25 and relatively high levels of GITR.
DISCUSSION
Past work has established that CD4 CD25  Treg cells develop
within the thymus (11, 20, 21). Furthermore, the narrow
window of time in which neonatal thymectomy renders
mice susceptible to organ-specific autoimmune disease indi-
cates that the early neonatal period is a critical time for seeding
the periphery with Treg cells (21–23). However, very little is
known concerning early developmental steps for the pro-
duction of Treg cells. It is within this context that we have
examined the trafficking and proliferation of CD4 CD25 
Treg cells, including an assessment of the contribution of IL-2.
This paper demonstrates that neonatal Treg cell development
occurs by rapid and extensive proliferation of these cells
within the lymph nodes that is followed by trafficking to
populate the spleen. Moreover, IL-2 drives the expansion of
Treg cells within the thymus and neonatal lymph nodes.
Our main approach to study the early developmental
events for Treg cell trafficking and proliferation was to adop-
tively transfer GFP  or allotype-marked (CD45.1) CFSE-
labeled purified CD4 CD25  T reg cells into newborn IL-
2R  /  mice. In 1-wk-old recipient mice, a near normal
complement of Treg cells, that had undergone considerable
proliferation, was detected in the lymph nodes, whereas very
few Treg cells were found in the spleen, and for these few
cells, no observable proliferation occurred. However, by 3 wk
after transfer, a readily measurable population of Treg cells
were seen in both the lymph nodes and spleen, and these
cells had completely diluted the CFSE label, indicating that
they were progeny of the initial engrafting Treg cells. As no
donor Treg cells were found in the thymus or bone marrow
during this time, these experiments indicate that lymph
nodes are the first secondary lymphoid organ where Treg cells
traffic and proliferate, followed by population of the spleen.
Mice deficient in IL-2, IL-2R , and IL-2R  contain
severely reduced numbers of CD4 CD25  Treg cells, espe-
cially in peripheral lymphoid tissue (11, 12). An important
advantage, therefore, of our adoptive transfer experiments is
that we can follow the trafficking and proliferation of donor
cells without competition from endogenously produced Treg
cells. Such competition readily occurs because when a similar
number of Treg cells were adoptively transferred to normal
mice, very few donor cells were found in peripheral lymphoid
tissues 4 wk later (12). It is highly likely that such competition
reflects that there is constant Treg cell production from new
thymic emigrants in normal recipient mice, which dilute the
donor cells, whereas the IL-2R  /  mice are solely depen-
dent upon donor Treg cells. Importantly, the induction of
autoimmunity by day 3 thymectomy (24) indicates that there
are not sufficient Treg cells in these lymph nodes at this time to
expand and effectively control autoimmune disease.
The appearance and number of Treg cells in the spleen and
lymph nodes from both normal or Tg /  mice were directly
shown to closely parallel that seen using the adoptive transfer
model. Therefore, the initial expansion of the Treg cells in the
adoptively transferred IL-2R  /  mice must approximate the
normal process to produce these cells. We also confirmed that
in all three of these models the phenotype of the CD4 
CD25  cells was that expected for Treg cells, i.e., predomi-
nately CD69low, CD62Lhigh, and GITRhigh. Although our
study did not directly address the homing of Treg cells upon
exit from the thymus, these data support the idea that during
the neonatal period Treg cells are generated in the thymus, exit
to the lymph nodes, and then traffic and populate the spleen.
Past work has shown that thymocytes that leave the thymus go
mainly to T cell areas of the lymph nodes, Peyer’s Patches, and
spleen with little migration to the bone marrow, gut, or liver
(25). The spleen is enriched in CD8  and    TCR  emi-
grants, whereas lymph nodes are enriched with CD4  emi-
grants, with the majority of lymph node emigrants expressing
L-selectin (26). CD4 CD25  T reg cells, therefore, are in-
cluded in this latter group of immediate thymic emigrants.
Figure 6. IL-2 is required for thymic production of CD4 CD25  Treg 
cells. All mice received either PBS ( ) or  -IL2 mAb ( ; 100  g) on the 
day and 3 d after birth. 7 d after birth, thymocytes from individual mice 
were subjected to FACS analysis with 250,000 events collected. In the data 
shown, the analysis of the indicated markers was performed after gating 
on CD4 CD8  “single positive” thymocytes. (A) The percent of thymic 
CD4 CD25  cells from B6 and Tg /  treated mice. Data are mean   SEM 
for six to eight animals per group. *P   0.05 compared with B6, and 
#P   0.001 compared with Tg /  (one-way analysis of variance followed 
by Newman-Keuls Multiple Comparison). (B) Dot plots for CD25 and GITR 
expression for thymic CD4 single positive thymocytes from B6 mice (left) 
and the absolute number of GITR  CD4 single positive thymocytes (right). 
Data are mean   SEM for three to four animals per group.JEM VOL. 201, March 7, 2005 775
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Based on their poor proliferative activity in vitro, Treg
cells have been considered anergic. However, more recent
studies indicate that it is possible to drive extensive prolifera-
tion of Treg cells in vitro, that in part requires high dose IL-2
(27, 28). Furthermore, adoptive transfer models demonstrate
that antigen-responsive Treg cells readily proliferate in adult
mice (29–33). Consistent with this idea, by enumerating the
number of donor Treg cells in adult IL-2R  /  recipients af-
ter neonatal adoptive transfer, we previously estimated that
there was at least 10–20-fold expansion of Treg cells (12).
Based on the current study, this degree of expansion is a sub-
stantial underestimation of the proliferation of Treg cells as
they expand in peripheral immune tissue. By six days after
adoptive transfer of CFSE-labeled Treg cells into IL-2R  / 
neonates,  50% of the donor CD4 CD25  T cells fully di-
luted the CFSE. This is equivalent to at least six to eight cells
divisions or a cycling rate of  24 h for these cells. Based on
these data and the number of Treg cells in 6-d-old neonatal
lymph nodes, it is now possible to estimate that the progeny
of Treg cells in such adoptively transferred mice were derived
by no more than 1,000–4,000 cells. It is conceivable that this
number may even be lower because at the time point used
for making this estimate many of the Treg cells fully diluted
their CFSE, so the number of cell divisions may have been
underestimated. In any case, we now estimate that to derive
a near normal complement (1–2   106 cells) of donor-derived
CD4 CD25  T cells in adult mice, there may be as much as
a 2,000-fold expansion of the Treg cells that initially seed the
neonatal lymph nodes. Proliferation by T cells in neonatal
lymph nodes is not a property unique for Treg cells. Substan-
tial proliferation by both conventional CD4  and CD8  T
cells has been noted within neonatal lymph nodes, the latter
of which is dependent upon IL-7 (34, 35).
This large expansion of donor Treg cells raise two poten-
tially important issues concerning the production of Treg
cells. First, this process results in amplification of the Treg
repertoire for those Treg cells that first seed the neonatal
lymph node. Such amplification may represent a mechanism
to rapidly generate suppressor cells to counteract autoreac-
tive T cells that escape thymic negative selection. This may
be especially meaningful during the neonatal period when
thymic negative selection is thought to be less stringent (34,
36), as the time-frame for thymic development is much
shorter. Second, only a relatively small fraction of injected
donor-derived Treg cells engraft the neonatal lymph nodes.
Based on the calculated number of Treg cells that initially en-
graft lymph nodes (1,000–4,000 as discussed above) and a re-
quirement to transfer  105 T reg cells to prevent lethal au-
toimmunity in C57BL/6 IL-2R  /  mice (12), it appears
that no more than 1–4% of the donor inoculum is responsi-
ble for engrafting the neonatal lymph nodes. This finding
raises the interesting possibility that only a particular subset
of Treg cells are competent to engraft and expand in neonatal
lymph nodes. Alternatively, this may simply reflect an inher-
ent inefficiency for engraftment or a size limitation for the
niche that accommodates Treg cells. Further study is required
to distinguish between these possibilities.
Much recent data support an important role for IL-2 in
the production of Treg cells in vivo (12–15). A very impor-
tant aspect of this study is that we have much more precisely
established the role of IL-2 in the production of Treg cells.
There appears to be two levels in which IL-2 is required for
Treg cells. One is to support Treg proliferation during devel-
opment in the thymus and second is to support extensive
proliferation as Treg cells seed the neonatal lymph nodes.
This is in line with the notion that IL-2 is a potent T cell
growth factor. An alternative idea is that IL-2 primarily pro-
vides a survival signal for the developing Treg cells and their
growth depends upon other molecules. This possibility
seems unlikely because providing IL-2 /  mice with survival
signals by transgenic expression of Bcl-2 in T lineage cells
did not mediate Treg cell production (37).
The interpretation of anti–IL-2 blockade for Treg pro-
duction in the normal mice is somewhat complicated and
most likely reflects effects within both the thymus and lymph
nodes. As such, evaluation of normal neonatal mice reflects a
composite of our other two models, which tend to discrimi-
nate developmental steps within the thymus versus the pe-
ripheral immune tissue. Thus, the low number of Treg cells
in lymph nodes in the adoptive transfer model after adminis-
tering anti–IL-2 directly reflects the need for IL-2 for the
rapid growth of these cells in this immune organ as donor
Treg cells are not detected within the thymus for 1-wk-old
IL-2R  /  recipient mice. In an analogous manner, Tg / 
mice are solely dependent upon thymic IL-2R expression
for Treg cell production (12, 16). Tg /  mice appear to
somewhat exaggerate the role for IL-2 within the thymus as
the most substantial inhibition for thymic Treg cells by anti–
IL-2 treatment was observed for Tg /  mice. This may par-
tially account for why Treg cells are readily found in the pe-
riphery of Tg /  mice without a need for expression of a
high affinity IL-2R. The basis by which Tg /  Treg cells ac-
cumulate in peripheral immune tissue in an IL-2–indepen-
dent manner is not known. Studies are in progress to further
explore the growth and homeostasis of Tg /  Treg cells in
peripheral immune tissues. In any case, this result provides
direct data that the increase of Treg cells within the thymus of
IL-2R  /  mice after thymic-specific transgenic expression
of IL-2R  was a consequence of IL-2–IL-2R signaling.
In conclusion, our data support a model in which initial
production of thymic CD4 CD25  Treg cells ensues with-
out IL-2. However, IL-2 provides necessary signals within
the thymus to increase their number. Upon trafficking to
neonatal lymph nodes, IL-2 is normally required to drive
substantial expansion of these cells. This does not exclude
other immune molecules, such as TCR–MHC class II and
B7–CD28 interactions, from contributing to this expansion,
as indicated by other studies (30–32, 38, 39). Interestingly, in
the latter case, the role for CD28–B7 appears to be due to its
ability to induce IL-2 production (39). It is likely that in theIL-2 IN TREG CELL DEVELOPMENT | Bayer et al. 776
absence of IL-2 in vivo, there are a few Treg cells or their
precursors. Thus, it should be possible to generate Treg cells
and potentially mediate suppression by IL-2 /  CD4  T
cells when IL-2 is available either directly or by transfer into
an IL-2 /  host. In fact, this has been observed several times
experimentally (15, 40). A key outstanding issue is whether
IL-2 is solely required for Treg cell growth or whether it
more broadly regulates Treg cell function. Recent experi-
ments indicate that IL-2 activation of Treg cells is necessary
for their suppressor activity in vitro, which is consistent with
a potential role for IL-2 in Treg cell function (28, 41).
MATERIALS AND METHODS
Mice. C57BL/6 were obtained from Jackson ImmunoResearch Laboratories.
B6.SJL-Ptprc/BoAiTac mice, congenic for CD45, were obtained from
Taconic and breed within our animal colony. IL-2R  /  mice, back-
crossed for at least 12 generations to C57BL/6 mice, have been described
previously (10). These mice were maintained by using breeding pairs that
were homozygous IL-2R  /  that were rendered autoimmune-free by
neonatal adoptive transfer of purified wild-type CD4  or CD4 CD25 
Treg cells (12). The thymic-targeted transgenic wild-type IL-2R  ex-
pressed in IL-2R  /  mice on the C57BL/6 genetic background (re-
ferred to as Tg /  in this study) has been described previously (16).
C57BL/6-Tg (ACTbEGFP)1Osb/J were provided by Dr. M. Okabe
(Osaka University, Suita, Japan; referred to as GFP in this study; 42). Protocols
were approved by the Institutional Animal and Use Committee at the
University of Miami.
Reagents. 5-(and 6-)carboxyfluorescein diacetate, succinimidyl ester
(CFSE) was purchased from Molecular Probes. Biotin-conjugated mAbs to
CD69 and CD103, and Cy-chrome (cyc)–conjugated mAbs to CD4 and
CD8, PE-conjugated anti-CD25 (PC61), PE-streptavidin, peridinin chlo-
rophyll-  protein (PerCP)–conjugated CD8 and CD4 mAbs, PerCP-
streptavidin, allophycocyanin (APC)-conjugated CD4 mAb, and APC-
streptavidin were purchased from BD Biosciences. Biotin-conjugated
GITR (also called TNFRSF18) mAb was purchased from R&D Systems.
FITC–anti-CD4 (GK1.5), biotin-conjugated mAbs to CD45.1 (A20),
CD62L (Mel14), CD25 (7D4), and CD44 (Pgp-1), and unlabeled anti–IL-2
mAb ( –IL-2, S4B6) were prepared in our laboratory.
Purification of CD4 CD25  T regulatory cells. Isolation of CD4 CD25 
T cells was described previously (12). In brief, splenic CD4 T cells were en-
riched by depletion of CD8  T cells and B cells. Viable cells were obtained
by centrifugation through lympholyte-M (Accurate Chemical and Scientific
Corp.). The enriched CD4 (100   106/ml) were then incubated with bi-
otin-conjugated anti-CD25 (10  g/ml), washed, and positively selected
with streptavidin MACS microbeads (Miltenyi Biotec). These cells were on
average  90% CD4 CD25  as assessed by flow cytometry. CFSE-labeled
Treg cells (20   106cells/ml) were prepared by addition of CFSE to a final
concentration of 2.5  M/ml for 10 min at 37 C followed by one wash with
RPMI 1640 containing 5% FBS, 1% penicillin-streptomycin, 1% ⅝-gluta-
mine, and 50  M 2-mercaptoethanol and two washes with HBSS.
Experimental animals. 1–2-d-old neonatal C57BL/6 IL-2R  /  mice
were adoptively transferred by i.v. injection of 2–5   105 of purified
CD4 CD25  Treg cells. These mice are indicated by T → IL-2R  /  in
this study. In all cases, these mice were devoid of symptoms associated with
IL-2R –deficiency at the time of sacrifice. In some experiments, neonatal
mice received an i.v. injection of either PBS or  –IL-2 mAb (100  g S4B6)
on the day they were born followed by an i.p. injection (100  g) 3 d later.
Inguinal, axillary, brachial, cervical, and mesenteric lymph nodes were col-
lected at the time of sacrifice along with the spleen, thymus, and bone mar-
row and subjected to FACS analysis.
FACS analysis. For three or four color analysis, cells were incubated for
20 min at 4 C with APC-CD4, PerCP-CD8, and PE-CD25 or biotin-
conjugated mAbs to CD45.1, CD25, CD44, CD69, CD62L, CD103,
GITR, or CD122 followed by two washes with HBSS containing 0.2%
BSA and 150 mM NaN3. Cells were then either used in FACS analysis or
incubated for 20 min at 4 C with APC-CD4, PE-CD25, and PerCP-
streptavidin, or cyc-CD4 and PE-streptavidin, or APC-CD4, PerCP-CD8,
and PE-Streptavidin, or PerCP-CD4, PE-CD25, and APC-streptavidin, or
FITC-CD4, PerCP-CD8, PE-CD25, and APC-streptavidin, or FITC-
CD4, cyc-CD8, and PE-streptavidin followed by a wash with same buffer,
as above. Cells were analyzed using a Becton Dickinson LSR1 and
CellQuest® software. GFP and CFSE fluorescence was detected using the
FL1 channel. The total number of events collected for analysis was between
50,000 and 100,000, unless otherwise stated in the figure legends.
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